Bionomics Ltd
ASX:BNO

Watchlist Manager
Bionomics Ltd Logo
Bionomics Ltd
ASX:BNO
Watchlist
Price: 0.01 AUD Market Closed
Market Cap: AU$13.5m

Net Margin

-9 450.3%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 450.3%
=
Net Income
AU$-24.9m
/
Revenue
AU$263.6k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 450.3%
=
Net Income
AU$-24.9m
/
Revenue
AU$263.6k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Bionomics Ltd
ASX:BNO
14.7m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 90% of companies in Australia
Percentile
10th
Based on 4 004 companies
10th percentile
-9 450.3%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Bionomics Ltd
Glance View

Market Cap
13.5m AUD
Industry
Biotechnology

Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The firm's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.

BNO Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-9 450.3%
=
Net Income
AU$-24.9m
/
Revenue
AU$263.6k
What is Bionomics Ltd's current Net Margin?

The current Net Margin for Bionomics Ltd is -9 450.3%, which is in line with its 3-year median of -9 450.3%.

How has Net Margin changed over time?

Over the last 3 years, Bionomics Ltd’s Net Margin has decreased from -1 615.3% to -9 450.3%. During this period, it reached a low of -15 255.7% on Jun 30, 2020 and a high of -1 615.3% on Dec 1, 2019.

Back to Top